文献速递免疫规划

结核疫苗H56+IC31的剂量反应曲线呈峰值型而非饱和型:为新数学建模方法生成数据以指导疫苗剂量决策

The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions.
PubMed 文献 · Vaccine · 2016-11-02

研究在小鼠中测量0、0.1、0.5、1、5或15μg H56+IC31接种后的IFN-γ分泌,比较不同剂量组的AUC、峰值和56天反应,并用校正Akaike信息准则检验剂量反应曲线类型。结果显示0.1和0.5μg组所有汇总指标高于对照组,0.1μg组AUC高于15μg组,各时间范围均强烈支持峰值型剂量反应曲线。

要点

  • 0.1和0.5μg剂量组所有汇总指标高于对照组(p<0.05)。
  • 0.1μg组AUC高于15μg组。
  • 各时间范围均强烈支持剂量反应曲线为峰值型,最佳剂量可能低于既往实验评估的剂量。

核心结论

  • 最高安全剂量在免疫原性方面可能并非总是最优,因为剂量反应曲线可能不饱和。
  • 结核疫苗H56+IC31在小鼠中的详细纵向剂量范围数据揭示了反应动态,应使用临床数据、新数据收集和数学建模来识别人类最佳剂量。

研究设计与样本

  • 研究测量了接受0、0.1、0.5、1、5或15μg H56+IC31剂量的小鼠脾细胞中IFN-γ分泌(ELISPOT法)。
  • 小鼠在第0天和第15天接种两次,首次接种后56天内8个时间点测量各剂量反应。
  • 比较剂量组间曲线下面积(AUC)、峰值和56天反应,并用校正Akaike信息准则检验不同时间范围哪种剂量反应曲线最佳拟合经验数据。

主要发现

  • 0.1和0.5μg剂量组的所有汇总指标均高于对照组(p<0.05)。
  • 0.1μg组的AUC高于15μg组。
  • 所有时间范围均有强烈证据表明剂量反应曲线为峰值型,最佳剂量可能低于既往经验实验评估的剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In vaccine development, dose-response curves are commonly assumed to be saturating. Evidence from tuberculosis (TB) vaccine, H56+IC31 shows this may be incorrect. Mathematical modelling techniques may be useful in efficiently identifying the most immunogenic dose, but model calibration requires longitudinal data across multiple doses and time points. AIMS: We aimed to (i) generate longitudinal response data in mice for a wide range of H56+IC31 doses for use in future mathematical modelling and (ii) test whether a 'saturating' or 'peaked' dose-response curve, better fit the empirical data. METHODS: We measured IFN-γ secretion using an ELISPOT assay in the splenocytes of mice who had received doses of 0, 0.1, 0.5, 1, 5 or 15μg H56+IC31. Mice were vaccinated twice (at day 0 and 15) and responses measured for each dose at 8 time points over a 56-day period following first vaccination. Summary measures Area Under the Curve (AUC), peak and day 56 responses were compared between dose groups. Corrected Akaike Information Criteria was used to test which dose-response curve best fitted empirical data, at different time ranges. RESULTS: (i) All summary measures for dose groups 0.1 and 0.5μg were higher than the control group (p<0.05). The AUC was higher for 0.1 than 15μg dose. (ii) There was strong evidence that the dose-response curve was peaked for all time ranges, and the best dose is likely to be lower than previous empirical experiments have evaluated. CONCLUSION: These results suggest that the highest, safe dose may not always optimal in terms of immunogenicity, as the dose-response curve may not saturate. Detailed longitudinal dose range data for TB vaccine H56+IC31 reveals response dynamics in mice that should now be used to identify optimal doses for humans using clinical data, using new data collection and mathematical modelling.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rhodes SJ, Zelmer A, Knight GM, et al. The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions. Vaccine. 2016. PMID: 27816373. doi:10.1016/j.vaccine.2016.10.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。